title: Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
authors.affiliation: Service de Néphrologie, Médecine Interne, Hopital Sud, Amiens, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Achard
authors.forename: A
authors.initials: A
authors.lastname: Pruna
authors.forename: L A
authors.initials: LA
authors.lastname: Fernandez
authors.forename: C
authors.initials: C
authors.lastname: Hottelart
authors.forename: H
authors.initials: H
authors.lastname: Mazouz
authors.forename: A
authors.initials: A
authors.lastname: Rosa
authors.forename: M
authors.initials: M
authors.lastname: Andrejak
authors.forename: A
authors.initials: A
authors.lastname: Fournier
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D020521:Stroke / Q000517:prevention & control*
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II